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Summary
Mucosa-associated lymphoid tissue (MALT) lymphoma is a common type of lymphoma in extranodal sites. The most
frequent chromosome translocation associated with MALT lymphoma is t(11;18)(q21;q21), which generates a chimeric
protein of c-IAP2 and MALT1/paracaspase. The c-IAP2/MALT1 fusion protein activates the NF-κB pathway, which is con-
sidered critical to malignant B cell transformation and lymphoma progression. The mechanism by which this fusion protein
activates NF-κB, however, remains unclear. Here we show that self-oligomerization of the c-IAP2/MALT1 protein causes
deregulated ubiquitin ligase activity of MALT1/paracaspase. The chimeric protein targets NEMO for polyubiquitination and
thereby activates NF-κB. Consistent with this finding, NEMO ubiquitination is increased in t(11;18)(q21;q21)-positive MALT
lymphoma samples. Thus, t(11;18)(q21;q21) deregulates MALT1/paracaspase ubiquitin ligase activity, causing constitutive
NF-κB activation and promoting tumorigenesis.S I G N I F I C A N C E
Chromosomal translocations are frequently associated with leukemias and lymphomas. Fusion oncoproteins that arise from chimeric
genes generated by such translocations often play critical roles in tumorigenesis. It is important, therefore, to understand the function
of the deregulated fusion protein in order to develop therapeutic interventions. The t(11;18)(q21;q21) is the most frequent chromo-
somal abnormality identified in MALT lymphoma. This translocation generates the c-IAP2/MALT1 fusion protein, which constitutively
activates NF-κB. Here we show that aberrant activation of NF-κB by the fusion protein stems from its deregulated ubiquitin ligase
activity. Thus, t(11;18)(q21;q21) represents a chromosomal translocation that produces a gain-of-function oncogenic ubiquitin li-
gase. The understanding of this pathway will be helpful for developing and testing molecularly targeted therapies.Introduction
Tumor development and progression are frequently associated
with genetic lesions that impact cell proliferation, cell survival,
angiogenesis, invasion, and metastasis (Hanahan and Wein-
berg, 2000). Many types of leukemias and lymphomas exhibit
chromosome abnormalities, such as translocations and non-
random gain and loss of chromosomes. Chromosome translo-
cations, in particular, have provided important clues to under-
standing the genetic basis of lymphomagenesis. Prominent
examples include t(14;18)(q32;q21) in human follicular lym-
phoma, t(8;14)(q24;q32) in Burkitt’s lymphoma, and the t(9;22)
Philadelphia chromosome in chronic myelogenous leukemia
(CML) (Rowley, 1998). These translocations are generally asso-
ciated with specific lymphoma subtypes, suggesting that they
are causal to disease. Cloning of genes at the translocation
breakpoints has greatly increased our understanding of these
oncogenic events. In human follicular lymphoma, the t(14;18)
translocation juxtaposes the antiapoptotic bcl-2 gene adjacent
to the immunoglobulin heavy chain (IGH) gene, resulting in in-
creased Bcl-2 expression (Rowley, 1998). In Burkitt’s lym-
phoma, the t(8;14) translocation juxtaposes the c-myc gene
adjacent to the IGH gene, causing upregulated c-Myc expres-
sion (Dalla-Favera et al., 1983). The Philadelphia chromosomeCANCER CELL : MAY 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INC.in CML places the Abelson (ABL) tyrosine kinase gene under
the regulation of the promoter for the breakpoint cluster region
(BCR) gene (de Klein et al., 1982). An in-frame chimeric gene
encodes a BCR/Abl fusion protein that is produced only in ma-
lignant cells. Consistent with a causal role for this translocation
in CML, inhibition of the deregulated tyrosine kinase activity of
the BCR/Abl oncoprotein by imatinib (also termed Gleevec) has
proved effective in treating t(9;22)-positive CML (Druker et al.,
2001).
MALT lymphoma is the most common extranodal non-Hodg-
kin’s lymphoma, arising in sites such as the stomach, lung, and
thyroid (Isaacson and Du, 2004). These lymphomas are com-
monly derived from a background of chronic inflammation or
autoimmune disease. For example, gastric MALT lymphoma is
often preceded by infection with Helicobacter pylori (H. pylori),
while thyroid MALT lymphoma is usually associated with Has-
himoto's thyroiditis. These observations suggest that persis-
tent inflammation may be linked to cell transformation.
t(11;18)(q21;q21) is the most frequent chromosomal aberration
associated with MALT lymphoma (Ye et al., 2003). This translo-
cation generates a chimeric transcript fusing the inhibitor of
apoptosis-2 (c-IAP2) gene on chromosome 11 to the MALT1
(mucosa-associated lymphoid tissue lymphoma translocation
gene 1) gene on chromosome 18. Intriguingly, the c-IAP2/DOI 10.1016/j.ccr.2005.04.012 425
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pression studies, but wild-type c-IAP2 and MALT1 do not
(Akagi et al., 1999; Dierlamm et al., 1999; Uren et al., 2000;
Lucas et al., 2001). c-IAP2 belongs to a family of IAP proteins
characterized by the presence of one to three baculovirus IAP
repeat (BIR) domains. c-IAP2 has three BIR domains, one cas-
pase-associated recruitment domain (CARD), and one RING
domain (Figure 1A). MALT1 contains a death domain (DD), two
immunoglobulin-like domains (Ig-like), and a region with ho-
mology to caspases (Figure 1A). This latter feature led to the
naming of MALT1 as human paracaspase. No protease activity
has been demonstrated for MALT1/paracaspase; rather, it par-
ticipates in NF-κB signaling downstream of the antigen recep-
tors by promoting ubiquitination of NEMO (Zhou et al., 2004;
Snipas et al., 2004). The fusion junctions between c-IAP2 and
MALT1/paracaspase have been well characterized (Figure 1A).
The c-IAP2/MALT1 fusion protein always comprises the N-ter-
minal portion of c-IAP2 with three BIR domains and the
C-terminal region of MALT1/paracaspase containing an intact
caspase-like domain (Akagi et al., 1999; Dierlamm et al., 1999;
Baens et al., 2000; Liu et al., 2000; Liu et al., 2001; Liu et al.,
2002; Ye et al., 2003). Selection for these domains of c-IAP2
and MALT1/paracaspase to form a functional fusion product
strongly suggests their importance and synergy in tumor devel-
opment.
The NF-κB family of transcription factors plays a key role in
inflammatory and innate immune responses (Li and Verma,
2002). In addition to its importance in immunity, persistent NF-
κB activation has been linked to the development of inflamma-
tion-associated tumors (Karin et al., 2002; Greten et al., 2004).
Indeed, many human leukemias and lymphomas show consti-
tutive NF-κB activation. The viral oncoprotein v-Rel, a member
of the NF-κB family, is sufficient for cell transformation in vitro
and in vivo (Gilmore, 1999). Oncogenic viruses, such as HTLV-1
and Epstein-Barr virus, also activate NF-κB (Karin et al., 2002).
Significantly, the ability of BCR/Abl to activate NF-κB was
shown to be essential for its oncogenic activity (Reuther et al.,
1998). NF-κB factors themselves are also deregulated in hu-
man tumors; many hematopoietic and solid tumors are associ-
ated with chromosomal aberrations involving the human c-rel,
rela, nfkb1, and nfkb2 genes (Karin et al., 2002).
Constitutive NF-κB activation by the c-IAP2/MALT1 fusion
protein is considered critical to malignant B cell transformation
and lymphoma progression in t(11;18)-positive MALT lym-
phoma. The cellular mechanism by which this fusion protein
activates NF-κB, however, has been unclear. Our data show
that the fusion protein self-oligomerizes and has deregulated
ubiquitin ligase activity. One target for ubiquitination by the
c-IAP2/MALT1 fusion protein is NEMO (also called IKKγ, NEMO
is the regulatory subunit of the IKK complex that has the cata-
lytic subunits IKKα and IKKβ), which leads to increased NF-κB
activity. Consistent with this notion, NEMO ubiquitination was
increased in t(11;18)-positive MALT lymphoma samples. Taken
together, these results suggest that the c-IAP2/MALT1 fusion
protein promotes lymphomagenesis through deregulated ubiqui-
tin ligase activity.
Results
The c-IAP2/MALT1 fusion protein induces ubiquitination
and NF-κB activation
To investigate the biochemical basis for constitutive NF-κB ac-
tivation by the c-IAP2/MALT1 fusion protein, we tested whether426Figure 1. c-IAP2/MALT1 fusion protein induces ubiquitination
A: Schematic representation of c-IAP2, MALT1/paracaspase (hPC), and
the cIAP2/MALT1 fusion protein (case2). BIR, baculoviral IAP repeat; CARD,
caspase recruitment domain; RING, really interesting new gene domain;
DD, death domain; Ig, immunoglobin-like domain.
B: Flag-case2, Flag-case2 mutant (C539A), Flag-hPC, or Flag-hPC mutant
(C539A) were cotransfected with HA-ubiquitin into 293T cells as indicated.
Total cell lysates were prepared and separated by SDS-PAGE. Total cellular
protein ubiquitination was analyzed by HA immunoblotting (top). Case2
and hPC expression levels were confirmed by paracaspase immunoblot-
ting (bottom).
C: Total cell lysates were incubated with or without USP2 in an in vitro de-
ubiquitination (DUB) assay. NEM, N-ethylmaleimide, a deubiquitinating en-
zyme inhibitor.
D: Flag-case2 was transfected with HA-ubiquitin (wt), HA-ubiquitin (K48
only), HA-ubiquitin (K63 only), or HA-ubiquitin (all Rs) as indicated. K63- or
K48-linked ubiquitination was determined by HA immunoblotting (top).
Case2 expression was confirmed by paracaspase immunoblotting
(bottom).
E: 293T cells pretreated with a control scramble siRNA (s) or siRNAs
targeting Ubc13 (Ubc13) were transfected with Flag-case2 and HA-ubiqui-
tin. Total cellular ubiquitination (top panel), Ubc13 protein expression (sec-
ond panel), and case2 expression (third panel) was determined by immu-
noblotting with the antibodies indicated. Western blotting for actin is
shown to demonstrate equal protein loading (bottom panel).
F: 293T cells were transfected with siRNAs, NF-κB reporter plasmids, and
case2 as indicated. NF-κB activation under the indicated conditions was
determined by NF-κB reporter assay.CANCER CELL : MAY 2005
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regulates cellular protein ubiquitination. When 293T cells were
cotransfected with case2 and hemagglutinin (HA)-tagged
ubiquitin, case2 increased the overall level of ubiquitin conju-
gates in total cell extracts (Figure 1B). In contrast, wild-type
MALT1/paracaspase or the C453A mutant of MALT1/paracas-
pase did not induce ubiquitination (Figure 1B). A case2 mutant
that had the conserved cysteine residue in the caspase-like
domain replaced with alanine induced total cellular ubiquitina-
tion similar to wild-type case2 (Figure 1B), so we conclude that
the increased ubiquitination was not dependent on the hypo-
thetical cysteine protease activity of MALT1/paracaspase.
Case2 and the case2 mutant also stimulated equivalent NF-κB
activation (data not shown). These results are consistent with
recent findings that the MALT1/paracaspase C453A mutant en-
hances rather than decreases Bcl10-stimulated NF-κB activa-
tion (Lucas et al., 2001; Zhou et al., 2004; Sun et al., 2004).
Thus, NF-κB activation by case2 or Bcl10 is not linked to any
predicted cysteine protease activity of MALT1/paracaspase.
Because case2 overexpression stimulates ubiquitination and
activates NF-κB, whereas MALT1/paracaspase expression
does neither, it is likely that these two events are mechanisti-
cally linked. We confirmed that the bands observed in Figure
1B were ubiquitin conjugates by incubating the cell lysates with
the deubiquitinating enzyme Usp2. Purified Usp2 abrogated
the bands, as revealed by anti-HA immunoblotting, indicating
that ubiquitin was cleaved from ubiquitinated proteins. Usp2
failed to cleave the ubiquitin conjugates in the presence of
NEM, an alkylating agent that inhibits deubiquitinating en-
zymes (Figure 1C).
Ubiquitination is a reversible posttranslational modification in
which the C terminus of 76 amino acid ubiquitin is conjugated
to a lysine residue in the target protein. The target protein can
be modified by addition of either a single ubiquitin moiety or a
polyubiquitin chain that has ubiquitins linked via specific lysine
residues. The type of ubiquitin linkage often determines the
fate of polyubiquitinated proteins. K48-linked polyubiquitina-
tion generally targets a protein for degradation in the protea-
some, whereas K63-linked polyubiquitination often regulates
protein function or protein-protein interactions (Pickart, 2001).
For example, recent studies have indicated that assembly of
signaling complexes required for activation of NF-κB involves
K63-linked ubiquitination of proteins such as TRAF2, TRAF6,
and NEMO (Burns and Martinon, 2004). To determine the pre-
dominant ubiquitin linkage induced by case2, 293T cells were
cotransfected with case2 and either wild-type ubiquitin, ubiqui-
tin that had all but one lysine (K48 or K63) mutated to arginine,
or ubiquitin that had all of its seven lysines changed to arginine.
Immunoblotting for the HA tag on the various ubiquitins re-
vealed that case2 increased cellular ubiquitination only when
K63 was available for conjugation (Figure 1D). K63-linked
ubiquitination can be catalyzed, in part, by the ubiquitin-conju-
gating E2 enzyme Ubc13 in a heterodimeric complex with
either Uev1a or Mms2 (Hofmann and Pickart, 1999; VanDe-
mark et al., 2001). We tested whether Ubc13 is required for
case2-induced ubiquitination and NF-κB activation by pretreat-
ing 293T cells with or without siRNAs targeting Ubc13. Knock-
down of Ubc13 protein abrogated both case2-induced total
cellular ubiquitination (Figure 1E) and NF-κB activation (Figure
1F). These data are consistent with the hypothesis that case2-CANCER CELL : MAY 2005induced ubiquitination is necessary for case2 to stimulate NF-
κB activation.
The BIR I domain is essential for case2-induced
NF-κB activation
To investigate the contribution of the BIR domains from c-IAP2
in case2-induced NF-κB activation, N-terminal deletion mu-
tants of case2 were generated (Figure 2A). These mutants were
transfected into 293T cells and tested for their ability to acti-
vate a NF-κB-dependent reporter gene. Case2 mutants lacking
BIR I failed to activate NF-κB, whereas the case2 mutant that
retained BIR I but lacked BIR II and BIR III stimulated consider-
able NF-κB activity (Figure 2B). These results indicate that the
BIR I domain from c-IAP2 is both necessary and sufficient for
NF-κB activation by the case2 fusion protein.
Previous studies have shown that Bcl10 promotes oligomer-
ization of MALT1/paracaspase to activate NF-κB (Zhou et al.,
2004; Sun et al., 2004). Because artificial crosslinking of the
caspase-like domain of MALT1/paracaspase has been shown
to activate NF-κB (Lucas et al., 2001; Zhou et al., 2004; Sun et
al., 2004), we tested whether the BIR domains from c-IAP2,
particularly BIR I, might oligomerize case2 and thereby activate
NF-κB. Flag-tagged case2 and either HA-tagged case2 or HA-
tagged case2 deletion mutants were cotransfected into 293T
cells. HA-case2 and the HA-case2 mutant retaining BIR I coim-
munoprecipitated with Flag-case2, whereas the HA-tagged
case2 mutants lacking BIR I did not associate with Flag-case2
(Figure 2C). These results show that the BIR I domain can serve
as an oligomerization motif and thus might regulate case2
function. Interestingly, the BIR domains of Op-IAP, another IAP
family member, have also been shown to mediate Op-IAP
oligomerization and regulate Op-IAP function (Hozak et al.,
2000). The BIR I-only case2 mutant, but not those mutants with
BIR I deleted, induced total cellular ubiquitination approaching
that of full-length case2 (Figure 2D), indicating that BIR I-medi-
ated oligomerization is essential for both ubiquitination and
NF-κB activation by case2.
An Ig-like domain C-terminal to the caspase-like domain
is required for NF-κB activation by case2
To investigate which domains from MALT1/paracaspase con-
tribute to NF-κB activation by case2, C-terminal deletion mu-
tants of case2 were generated (Figure 3A). Surprisingly, case2
del1 mutant, which has an intact caspase-like domain but
lacks further C-terminal amino acids, could not activate ex-
pression of a NF-κB-dependent reporter gene (Figure 3B).
Closer examination of the C terminus of MALT1/paracaspase
revealed an Ig-like domain following the caspase-like domain.
An additional 100 amino acids come after the Ig-like domain,
but these do not resemble any known structural motif (Figure
3A). Retention of the Ig-like domain was found to be necessary
for NF-κB activation, while the last 100 amino acids were dis-
pensable (Figure 3B). These results indicate that the C-terminal
Ig-like domain from MALT1/paracaspase is required for NF-κB
activation by case2.
Recently, two consensus TRAF6 binding motifs were re-
ported to be present in the C terminus of MALT1/paracaspase
(Sun et al., 2004), and it was suggested that the Bcl10/MALT1/
paracaspase complex engages TRAF6 to activate NF-κB. Both
TRAF6 binding sites were deleted in the case2 del1 mutant, so
we further investigated the contribution of these two sites to427
A R T I C L EFigure 2. BIR I domain is essential for case2-induced NF-κB activation
A: Schematic representation of case2 and case2 deletional mutants. Full-
length (FL) case2 was compared to deletion mutants lacking either the BIR
I domain alone (BIR I case2), both BIR I and BIR II (BIR III only case2), or BIR
II and BIR III domains (BIR I only case2).
B: 293T cells were transfected with NF-κB reporter plasmids together with
case2 or case2 mutants as indicated. NF-κB activation fold was deter-
mined by NF-κB reporter assay relative to the vector control. Data repre-
sent mean ± SEM of three independent experiments. BIR I case2 failed to
stimulate NF-κB activation, whereas BIR I only case2 still activated NF-κB.
C: Flag-case2 and either HA-case2 or HA-tagged case2 deletion mutants
were transfected into 293T cells. Interactions between Flag-case2 and HA-
tagged case2 deletion mutants were determined by immunoprecipitation
with Flag monoclonal antibody followed by immunoblotting with antibody
to HA.
D: HA-case2 or HA-case2 deletional mutants were transfected with Flag-
ubiquitin into 293T cells. Ubiquitination was determined by immunoblotting
for Flag.428Figure 3. An Ig-like domain in the C terminus of MALT1/paracaspase is re-
quired for NF-κB activation by case2
A: Schematic representation of case2 and case2 deletional mutants. FL:
full length case2; case2 /caspase-like domain; case2/caspase-like domain
plus Ig-like domain.
B: 293T cells were cotransfected with NF-κB reporter plasmid and either
case2 or case2 deletions as indicated. NF-κB fold activation was deter-
mined by NF-κB reporter assay relative to the vector control. Data repre-
sent mean ± SEM of three independent experiments.
C: 293T cells were transfected with NF-κB reporter plasmids together with
case2, case2 (E653A), case2 (E806A), or case2 (E653A/E806A; AA) as indi-
cated. Data are expressed relative to case2 control and represent the
mean ± SEM of three independent experiments.
D: Ubc13 and HA-case2 or HA-tagged case2 deletion mutants were trans-
fected into 293T cells. Association between Ubc13 and HA-tagged case2
deletion mutants was determined by immunoprecipitation with HA mono-
clonal antibody followed by immunoblotting with anti-Ubc13 antibody.case2-induced NF-κB activation by generating full-length
case2 point mutants E653A, E806A, and E653A/E806A (Figure
3C). All three case2 mutants activated NF-κB (Figure 3C), indi-
cating that these potential TRAF6 binding sites may not be re-
quired for case2 to activate NF-κB.
Because Ubc13 is required for case2-induced NF-κB activa-tion (Figure 1E), and because we have shown previously that
the C-terminal half of MALT1/paracaspase catalyzes ubiquiti-
nation together with Ubc13/Mms2 (Zhou et al., 2004), we
tested whether the C-terminal deletions of case2 impacted E2
binding. HA-case2 or HA-tagged case2 deletion mutants were
cotransfected with Ubc13 into 293T cells. Ubc13 coimmuno-
precipitated with full-length case2 and the case2 del2 mutant,
which retains the Ig-like domain. No interaction was observed
between Ubc13 and the case2 del1 mutant lacking the Ig-like
domain (Figure 3D). The importance of this Ig-like domain in
case2 for the recruitment of Ubc13 offers an explanation forCANCER CELL : MAY 2005
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tivate NF-κB (Figure 3B) or increase total cellular ubiquitination
(data not shown).
Case2 induces NEMO ubiquitination
To determine whether case2 activates NF-κB in a fashion sim-
ilar to Bcl10 (Zhou et al., 2004; Sun et al., 2004), we tested
whether case2 increased ubiquitination of cotransfected NEMO
in 293T cells. Detection of ubiquitin conjugates was facilitated
by transfection of HA-tagged ubiquitin. Case2 did induce
NEMO ubiquitination, as determined by immunoblotting with
NEMO and HA (Figure 4A). NEMO has a highly conserved ly-
sine residue (K399) within its zinc finger, which, when mutated
to arginine, markedly decreased NEMO ubiquitination in re-
sponse to case2 (Figure 4A). The significance of polyubiquiti-
nation on K399 within NEMO to case2-induced NF-κB activa-
tion was assessed by transfecting case2 into NEMO-deficient
5R cells. Consistent with a previous study, case2 did not acti-
vate NF-κB in NEMO-deficient 5R cells (Lucas et al., 2001; Fig-
ure 4B). Significantly, 5R cells reconstituted with wild-type
NEMO activated NF-κB in response to case2, but activation of
NF-κB was much weaker when cells were reconstituted with
the NEMO K399R mutant (Figure 4B). These results indicate
that ubiquitination of NEMO on K399R is important for full NF-
κB activation by case2. The contribution of ubiquitination to
case2-induced NF-κB activation was confirmed using the de-
ubiquitinating enzyme CYLD; case2-induced NF-κB activation
in 293T cells was suppressed effectively by CYLD (Figure 4C),
and this suppression correlated with a severe reduction in
NEMO ubiquitination (Figure 4D).
NEMO ubiquitination is increased in t(11;18) MALT
lymphoma tumor samples
Next, we examined the ubiquitination status of NEMO in
t(11;18)-positive MALT lymphoma samples that transcribed
c-IAP2/MALT1 fusion genes. c-IAP2/MALT1 fusion proteins
could be detected by Western blotting in two t(11;18)-positive
MALT lymphoma samples (G5661 and G6071), but, as ex-
pected, were not detected in human tonsil samples (Figure 4E).
NEMO ubiquitination in these samples was examined by im-
munoprecipitation with NEMO antibody followed by immu-
noblotting with anti-ubiquitin antibody (Figure 4E). More poly-
ubiquitinated NEMO was observed in the two MALT lymphoma
samples than in the normal tonsil samples (Figure 4E), while
total NEMO levels in the four samples were equivalent (Figure
4E). These data are consistent with the notion that the c-IAP2/
MALT1 fusion protein drives NEMO ubiquitination in MALT lym-
phoma cells.
Discussion
A causal relationship between inflammation and cancer has
been suspected for many years, but the link between the two
remains poorly understood. Chronic infection and inflammation
might affect cells directly or indirectly to promote their malig-
nant transformation. In gastric MALT lymphoma, the t(11;18)
translocation is closely linked to infection with CagA-positive
strains of H. pylori (Ye et al., 2003), which elicit significant in-
flammatory responses. It is tempting to speculate that the
t(11;18) translocation occurs in premalignant lesions as a con-
sequence of persistent B cell activation during chronic infec-CANCER CELL : MAY 2005Figure 4. Case2 induces NEMO ubiquitination
A: HA-ubiquitin and Myc-case2, wild-type NEMO (wt), or NEMO mutant
K399R (mt) were transfected into 293T cells. NEMO ubiquitination was de-
termined by immunoblotting for NEMO (left) and HA (right).
B: NEMO-deficient 5R cells were cotransfected with case2 and NEMO (wt)
or NEMOmutant K399R (mt). Case2-stimulated NF-κB activation was deter-
mined by NF-κB reporter assay. Data represent the mean ± SEM of three
independent experiments.
C: A NF-κB reporter plasmid and case2 were transfected into 293T cells with
or without CYLD. NF-κB activation was determined by NF-κB reporter assay.
D: HA-ubiquitin, NEMO, and case2 were transfected into 293T cells with or
without CYLD. NEMO ubiquitination was detected by immunoblotting with
anti-HA and anti-NEMO antibodies.
E: Expression of c-IAP2/MALT1 fusion proteins in two t(11;18)-positive MALT
lymphoma samples (G5661, G6071) was determined by immunoblotting
with anti-paracaspase antibody (top panel). Normal human tonsil samples
were used as negative controls (Ton1, Ton2). Ubiquitination of NEMO, which
was first immunoprecipitated from denatured lysates (Zhou et al., 2004),
was determined by immunoblotting with anti-ubiquitin antibody as indi-
cated.tion, and that expression of the c-IAP2/MALT1 fusion protein
then drives progression to MALT lymphoma. Unfortunately,
attempts to generate transgenic mice expressing the c-IAP2/
MALT1 fusion protein in the B cell lineage have been unsuc-
cessful (V.M.D., unpublished data), so it remains to be seen
whether expression of the c-IAP2/MALT1 fusion protein alone
promotes tumor development.429
A R T I C L ETwo other rare, but recurrent, chromosomal translocations
found in MALT lymphoma are t(1;14)(p22;q32) (Isaacson and
Du, 2004) and t(14;18)(q32;q21) (Sanchez-Izquierdo et al.,
2003; Streubel et al., 2003). t(1;14)(p22;q32) juxtaposes the
bcl10 gene to the immunoglobin (Ig) locus, resulting in upregu-
lated Bcl10 expression. t(14;18)(q32;q21) places the MALT1
gene under the control of the enhancer region of the IGH gene
and elevates MALT1/paracaspase expression. Both Bcl10 and
MALT1/paracaspase are required for antigen receptor-stim-
ulated NF-κB activation and lymphocyte proliferation (Ruland
et al., 2001, 2003; Ruefli-Brasse et al., 2003; Zhou et al., 2004).
In fact, Bcl10 and MALT1 form a complex and synergize in the
activation of NF-κB-dependent gene transcription (Lucas et al.,
2001). Given that the c-IAP2/MALT1 fusion protein also acti-
vates the NF-κB pathway, it seems likely that all three distinct
chromosomal translocations contribute to MALT lymphoma
pathogenesis by allowing antigen-independent NF-κB activa-
tion to promote growth and expansion of the lymphoma clone.
Recently, it was suggested that MALT1/paracaspase recruits
TRAF6 to activate NF-κB signaling (Sun et al., 2004). T cells
from TRAF6-deficient mice, however, are reported to proliferate
normally in response to crosslinking antibodies to CD3 and
CD28 (Lomaga et al., 1999). By contrast, Bcl10- or MALT1/
paracaspase-deficient T cells neither activate NF-κB nor prolif-
erate upon TCR engagement (Ruland et al., 2001, 2003; Ruefli-
Brasse et al., 2003). These observations argue against an
essential role for TRAF6 downstream of Bcl10 and MALT1/
paracaspase in antigen receptor-stimulated NF-κB activation.
Mutation of the proposed TRAF6 binding sites in case2 did
not attenuate case2-induced NF-κB activation (Figure 3C), nor
could we detect the association of TRAF6 with case2 (Supple-
mental Figure S1). In addition, siRNA-mediated knockdown of
TRAF6 did not inhibit case2-stimulated NF-κB activation (Sup-
plemental Figure S2). These results suggest that the fusion pro-
tein engages NF-κB in a TRAF6-independent manner, although
it cannot be ruled out that another member of the TRAF family
might substitute for TRAF6.
Overexpressed case2, like Bcl10 (Zhou et al., 2004), induces
ubiquitination of NEMO (Figure 4A), and this is required for full
activation of NF-κB. It remains to be determined whether
ubiquitination of NEMO contributes to IKK complex activation
by recruiting an upstream activating kinase or by altering IKK
complex conformation to cause autoactivation. The observa-
tion that a NEMO mutant defective in ubiquitination supports
NF-κB activation, albeit to a lesser degree, indicates that addi-
tional molecules are likely involved. In a physiological setting,
antigen receptor stimulation triggers assembly of the Bcl10-
containing signaling complex, which oligomerizes paracaspase
and promotes ubiquitin ligase activity (Zhou et al., 2004).
Based on our current findings, we propose that the c-IAP2/
MALT1 fusion protein generated by the t(11;18) translocation is
constitutively active and bypasses the normal requirement for
Bcl10-mediated oligomerization of MALT1/paracaspase. The
observation that the c-IAP2/MALT1 fusion protein stimulates
NF-κB activation in Bcl10-deficient cells would support this
notion (Ruland et al., 2003). t(11;18) is often associated with a
more aggressive clinical behavior and is used to predict the
therapeutic response of gastric MALT lymphoma to H. pylori
eradication. t(11;18)-negative MALT lymphoma often regresses
in response to antibiotic therapy, while t(11;18)-positive MALT
lymphoma is H. pylori-independent and does not respond to430antibiotics, suggesting that c-IAP2/MALT1 activates NF-κB suf-
ficiently to stimulate antigen-independent growth.
In summary, our study provides an example of a chromo-
somal translocation that contributes to a human malignancy
by impacting the activity of an ubiquitin ligase. Given that the
ubiquitin/proteasome (UPS) system is involved in multiple as-
pects of cell proliferation, differentiation, and survival, it is likely
that UPS deregulation will emerge as a critical factor in tumori-
genesis. Drugs such as the general proteasome inhibitor Vel-
cade, which has been approved for multiple myeloma therapy,
will hopefully exploit this possibility. For t(11;18)-positive MALT
lymphoma, specific inhibition of c-IAP2/MALT1 ubiquitin ligase
activity might be beneficial.
Experimental procedures
Cells, cell culture, antibodies, plasmids,
and MALT lymphoma samples
Human kidney epithelial (HEK) 293T cells were grown in DMEM supple-
mented with 10% FBS at 37°C in the presence of 10% CO2. All constructs
for mammalian protein expression were generated in the pRK5B vector with
a Flag- or HA-epitope tag placed at the NH2-terminal of the protein as
indicated. The breakpoint in the cIAP2 gene from both G5661 and G6071
is nucleotide 2048. The breakpoint in the MALT1 gene in G5661 and G6071
is nucleotide 1123 and 814, respectively.
RNA interference
HEK 293T cells were transfected with double-stranded siRNAs using Lipo-
fectamine 2000 (Invitrogen). 21-bp RNA oligonucleotides targeting Ubc13
were synthesized by Dharmacon as described previously (Zhou et al.,
2004). 36 hr after adding siRNAs, cells were transfected with the indicated
expression plasmids and cultured for an additional 36 hr before harvesting.
NF-κB reporter assay
293T and 5R cells were transfected with the indicated plasmids using Lipo-
fectamine 2000 (Invitrogen). 36 hr posttransfection, NF-κB luciferase activ-
ity was measured using the Promega Dual Luciferase Reporter Assay sys-
tem (normalized to control luciferase activity) as previously described (Zhou
et al., 2004).
Western blotting and immunoprecipitation
24 to 36 hr after transfection, cells were lysed in 1% NP-40 lysis buffer (50
mM HEPES [pH 7.5], 150 mM NaCl, 10% glycerol, 2 mM DTT, 1% NP40,
1 mM EDTA) and immunoprecipitated with anti-FLAG M2 agarose (Sigma).
The total cell lysates and immunoprecipitates were resolved by SDS-PAGE
and analyzed by immunoblotting with the indicated antibodies.
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/5/425/DC1/.
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